= LhARA Steering Group meeting !#3 = //**3^rd^ July 2020 10:00 GMT**// **Present:** KL, KK, SG, CB, CH, CW, JPa, JPar, JC, PA, RMcL, AP, TKW == Summary of actions == * **KL**: Set up series of meetings with leads at partner organisations to discuss preparation of R&D programme. * **KL/CB**: Consider meeting between Imperial (and other) ion-accelerator experts with the relevant experts in CLF. * **KL/KK**: to collaborate on the development for a proposal for such a meeting on the timescale of November 2020. * **KL**: Ensure one representative per group at the next LhARA SG meeting. * **KL**: Raise NIHR engagement with K.Gleeson. * **KL**: Seek PPI representative for SG. * **KK, JPar, CW, KL**: Make relevant contact with local PPI groups as described in item 4. * **KL&JPar**: Write to CTRAD w/s 4 chair (KK) to ask how we might work together to raise awarenents of our programme among the patient and clinician communitites. * **KK, JPar, CW, KL, SG**: Make relevant contact with local clinician groups as described in item 4. * **KL**: Write to J.Clarke to ask for support to reach out to relevant industry. * **PA**: Make contact with MTC to see how to make contact with relevant industry. **PA/KL** will cooperate in drafting a letter. * **KL**: Review proposed w/p structure and skills matrix taking into account comments under item 4. * **KL/RMcL**: Liaise to generate small group to coordinate development of instrumentation aspects of the programme. == Notes == 1. [wiki:Research/DesignStudy/SteeringGroup/2020-06-05 Notes of last meeting and actions arising:] * **KL**: Set up series of meetings with leads at partner organisations to discuss preparation of R&D programme. * **Ongoing.** Need to step up the priority of this activity as we prepare the EPSRC proposal. * **KL/CB**: Consider meeting between Imperial (and other) ion-accelerator experts with the relevant experts in CLF. * **Stands.** This meeting is necessary and, probably, should include Strathclyde and Belfast. Agreed, morph action to include all. * **KL/KK** to collaborate on the development for a proposal for such a meeting on the timescale of November 2020. * **Stands.** Agenda item. * **KL** Send out diary invitation straight away to get it into the diary. * **Done.** 2. [raw-attachment:2020-07-03-Progress-update.pdf Update on progress]: KL \\ See slides which contain a brief status report as well as the provocation of the discussion for agenda item 4. 3. Discussion of SG composition: KL/All - We agreed to re-set the SG composition to include one representative per group, the work-package managers (once they are defined), and co-opted members as required. **KL** will work towards proper representation at the next SG meeting. - JPar noted that it would be important to make sure that groups were represented in the meeting and insitute Directors may need to be encouraged to delegate appropriately. 4. [https://epsrc.ukri.org/funding/calls/second-call-for-transformative-healthcare-technologies-pre-announcement-and-engagement-event/ EPSRC Transformative Healthcare Technologies call]: KL/All * Dealing with feedback from our 2019 submission: \\ "//Engagement with patients, clinicians and industry could have been strengthened//" - Patient engagement: - Actions taken to date include engagement with the PPI group at CXH in London. These contacts will be taken forward. - We **agreed**: - Make local contacts by partner: - **KK**: Manchester - **JPar**: Liverpool - **CW**: Glasgow -- JPar will help with introduction to Anthony Chalmers, ex chair of CTRAD - **KL**: Will contact K.Prise in Belfast to see whether/how contact to PPI can be made. - With local contacts made we'll try and coordinate broader activity, Perhaps K.Gleeson (CXH) may take a role here. - CTRAD: important to bring Workstreams 1 and 4 into the patient- and clinician-engagement activities. **KL&JPar** will write to KK in her capacity as W/s4 chair to ask for help in this regard. - NIHR: Various local groups, including one in London with which K.Gleeson is in contact. Seek to exploit NIHR. **KL** will raise possibility with K.Gleeson. - General comment from SG: need to ask what is important to patients. We discussed co-opting a PPI member to our SG. **KL** agreed to ask the author of the Lay Summaries of the pre-CDR and the publication if he would be willing to play this role. - Clinician engagement: - Within Imperial Trust and College contacts with clinicians and medical physicists good and being strengthened. We discussed the need to develop links with clinicians at the various partner institutes. We **agreed**: - **SG**: Birmingham - **JPar**: Liverpool - **KK**: Manchester (perhaps in collaboration with N. Burnett) - **CW**: Glasgow -- JPar will help with introduction to Anthony Chalmers, ex chair of CTRAD - **KL**: Contact K. Prise and M. Borghesi re clinician contact in Belfast. - As in the case of patient engagement we **agreed** to contact CTRAD to seek support in reaching out. **KL/JPar** will write to the KK to seek support in this endeavour. - Industrial engagement: - Some contacts made at time of preparation of last meeting and need to push forward to enhance the industrial engagement going forward. After discussing how to proceed we **agreed**: - **KL**: Will write to J.Clarke to ask for support to reach out to relevant industry. - **PA**: Will make contact with MTC to see how to make contact with relevant industry. **PA/KL** will cooperate in drafting a letter. - Possible engagement: Teledyne-E2V; Oxford Instruments, FMD-Oxford, STFC engagement team. - We noted the possibility that we should get a person to coordinate our industrial engagement. * Slides to initiate discussion of (done under 2 above): - Scope: we agreed to target first radiobiology exposures on LhARA within the 5-year scope of the bid. - We discussed the w/p structure. KK pointed out that it needed to map explicitly to the EPSRC priority deliverables. **KL** will take a second look at the proposed w/p structure and propose a revision. - Stakeholders from whom we should be seeking support; --All-- - TKW proposed to make a diagram showing expertise required vs expertise available. **KL** will coordinate the creation of such a diagram. This diagram will also be valuable in negotiations with partners. 5. Follow-up discussion of dedicated advanced diagnostics and instrumentation for the //in vitro// and //in vivo// end stations: KL/all - KL reported that R.McLauchlan (CXH) had agreed to take an overview/coordinating role in this area. RMcL explained the vision to bring people together to understand what the opportunities are and how to bring the activity together into a coherent programme. - PA pointed out the need to take a staged approach with an initial focus on making sure the beam delivered is appropriate. - JPar pointed out that Liverpool has a Centre for Pre-Clinical Imaging. - We agreed to work towards a small sub-group to guide the development of the meeting and subsequently guide the development of the activity. **KL/RMcL** will liaise to bring this about. 6. DONMs \\ * 04 Sep 2020; 10:00 BST 7. AoB \\ - None. ---- == Agenda == 1. [wiki:Research/DesignStudy/SteeringGroup/2020-06-05 Notes of last meeting and actions arising:] * **KL**: Set up series of meetings with leads at partner organisations to discuss preparation of R&D programme. * **Ongoing.** Need to step up the priority of this activity as we prepare the EPSRC proposal. * **KL/CB**: Consider meeting between Imperial (and other) ion-accelerator experts with the relevant experts in CLF. * **Stands.** This meeting is necessary and, probably, should include Strathclyde and Belfast. * **KL/KK** to collaborate on the development for a proposal for such a meeting on the timescale of November 2020. * **Stands.** Agenda item. * **KL** Send out diary invitation straight away to get it into the diary. * **Done.** 2. [raw-attachment:2020-07-03-Progress-update.pdf Update on progress]: KL \\ 3. Discussion of SG composition: KL/All 4. [https://epsrc.ukri.org/funding/calls/second-call-for-transformative-healthcare-technologies-pre-announcement-and-engagement-event/ EPSRC Transformative Healthcare Technologies call]: KL/All * Dealing with feedback from our 2019 submission: \\ "//Engagement with patients, clinicians and industry could have been strengthened//" - Patient engagement: - Actions taken to date; - Need for local action by partner; - Subsequent coordination - Clinician engagement: - Actions taken to date; - Need for local action by partner; - Subsequent coordination - Industrial engagement: - Actions taken to date; - Discussion of next steps * Slides to initiate discussion of: - Scope; - Initial discussion of work packages; - Stakeholders from whom we should be seeking support; * Next steps discussion 5. Follow-up Discussion of dedicated advanced diagnostics and instrumentation for the //in vitro// and //in vivo// end stations: KL/all 6. DONMs \\ * 04 Sep 2020; 10:00 BST 7. AoB \\ ----